Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà
MedNavigator.ru - Ïîèñê è ïîäáîð ëå÷åíèÿ â Ðîññèè è çà ðóáåæîì
  #706  
Ñòàðûé 09.08.2013, 22:53
Àâàòàð äëÿ Korzun
Korzun Korzun âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 15.03.2005
Ãîðîä: Ãåðìàíèÿ
Ñîîáùåíèé: 24,467
Ñêàçàë(à) ñïàñèáî: 1
Ïîáëàãîäàðèëè 10,461 ðàç(à) çà 9,629 ñîîáùåíèé
Korzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
È åùå îäíî ñîîáðàæåíèå.
Åñëè âñåì-âñåì ïîâåñèòü Õîëòåðû, òî ó ñêîëüêèõ "çäîðîâûõ" áóäóò âûÿâëåíû êîðîòêèå (1-2-10 ìèíóò) ïàðîêñèçìû ÔÏ? À åñëè 48-÷àñîâûå èëè ðåâèëû?
À êòî äåëàë ÝÔÈ çíàåò, ÷òî ñòèìóëÿöèåé ìîæíî çàâåñòè ÔÏ ïðàêòè÷åñêè êàæäîìó.
Ãäå òà ãðàíü, êîãäà ÔÏ ìîæíî íàçâàòü íîçîëîãèåé?

Íàïðèìåð, ìîëîäàÿ äåâóøêà - ýòî óæå 1 áàëë (çà ïîë), íà Õîëòåðå ñëó÷àéíî íàøëè ÔÏ äëèòåëüíîñòüþ 1 ìèíóòà, æàëîá íåò, ÷òî äåëàòü? Ïðàäàêñà èëè Êñàðåëòî?
__________________
Àëåêñàíäð Èâàíîâè÷
ñ ïîæåëàíèÿìè êðåïêîãî çäîðîâüÿ
Îòâåòèòü ñ öèòèðîâàíèåì
  #707  
Ñòàðûé 10.08.2013, 05:51
BMB BMB âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 12.10.2010
Ãîðîä: Êðàñíîÿðñê
Ñîîáùåíèé: 276
Ñêàçàë(à) ñïàñèáî: 113
Ïîáëàãîäàðèëè 15 ðàç(à) çà 15 ñîîáùåíèé
BMB ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBMB ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBMB ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBMB ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïî ïîâîäó êîíêðåòíîãî ïàöèåíòà (ïðî êîòîðîãî ÿ âîïðîñû çàäàë): íà ôîíå òèðåîòîêñèêîçà ó íåãî ïàðó ìåñÿöåâ êëèíèêà òèðåîòîêñèêîçà, â òîì ÷èñëå ñåðäöåáèåíèå ïðè âîëíåíèè, ôèç. àêòèâíîñòè, îñîáåííî â ïîñëåäíèå 2 íåäåëè, â ïîêîå ñèíóñîâûé ðèòì ñ ÷ññ 100 â ìèí. Âî âðåìÿ 16-ìèíóòíîãî ýïèçîäà ôï ïî ÕÌ - ÷óâñòâîâàë îñîáåííî ñèëüíîå ñåðäöåáèåíèå, òàê ÷òî îí ñêîðåå ÷óâñòâóåò ôï, ÷åì íåò, íî ñóáúåêòèâíî ÷åòêî íå ðàçëè÷àåò - êîãäà ó íåãî ñèíóñîâàÿ òàõè, êîãäà ôï.  ëþáîì ñëó÷àå - äî ïîñëåäíèõ 2 íåäåëü èëè 2 ìåñ. òàêîãî ñåðäöåáèåíèÿ îí íå ÷óâñòâîâàë.
Ïî ïîâîäó ìîëîäîé äåâóøêè ñ 1-ìèíóòíîé ôï íà ÕÌ - â åâðîïåéñêîì àïäåéòå: Female patients who are aged <65 and have lone AF (but still have a CHA2DS2-VASc score of 1 by virtue of their gender) are low risk and no antithrombotic therapy should be considered (IIA LOE B)
Íó è ïî ïîâîäó çäîðîâûõ, êîòîðûì ìîæíî äåëàòü õîëòåðû èëè èìïëàíòèðîâàòü REVEAL - ÿ íå çíàþ, êàêîâà áóäåò ðàñïðîñòðàí¸ííîñòü áåññèìïòîìíîé ôï, íàâåðíîå òàêèå äàííûå åñòü, íî ÿ íå âèäåë. Èíòåðåñíåå âîïðîñ - à ÷òî ñ òàêèìè ïàöèåíòàìè ïîòîì äåëàòü. Íà êàðäèîëîãè÷åñêîì êîíãðåññå ïðîøëîé îñåíüþ â Ìîñêâå Ïîêóøàëîâ èç ÍÈÈ ÏÊ ðàññêàçûâàë îá èññëåäîâàíèè [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] - â í¸ì êàê ðàç ïûòàëèñü ñ ïîìîùüþ èìïëàíòèðîâàííûõ äåâàéñîâ îïðåäåëèòü êîðåëëÿöèþ ìåæäó AF burden è ðèñêîì ðàçâèòèÿ ÎÍÌÊ. Ó íèõ ïîëó÷èëîñü, ÷òî áîëåå 5,5 ÷àñîâ â ñðåäíåì çà ñóòêè ïðè ïîäñ÷åòå çà ìåñÿö - ïîâûøåííûé ðèñê ÎÍÌÊ. Ïîêóøàëîâ ãîâîðèë, ÷òî ïî äðóãèì äàííûì ýòîò ïîðîã 3,7 ÷/ñóòêè. Ýòî âñ¸ åùå ñòî ðàç ïîìåíÿåòñÿ íàâåðíîå, íî èññëåäîâàíèÿ â ýòîì íàïðàâëåíèè èäóò, âûãëÿäèò ýòîò ïîäõîä ëîãè÷íî. Òàê ÷òî ìîæåò áûòü â áóäóùåì ðåøåíèå îá àíòèêîàãóëÿöèè áóäåò ïðèíèìàòüñÿ ñ ó÷åòîì íå òîëüêî CHA2DS2-VASc (èëè ïîäîáíîé øêàëû) è íàëè÷èÿ ôï êàê òàêîâîé, íî è ñ ó÷åòîì AF burden (áëèí, ïëîõî çíàþ íå òîëüêî àíãë, íî è ñâîé ðîäíîé ðóññêèé - íå ìîãó íîðìàëüíî àäåêâàòíî çàìåíèòü äîâîëüíîå ïðîñòî¸ àíãë. ïîíÿòèå àäåêâàòíûì ðóññêèì)

Êîììåíòàðèè ê ñîîáùåíèþ:
Korzun îäîáðèë(à): à ÷òî ñ òàêèìè ïàöèåíòàìè ïîòîì äåëàòü?
Îòâåòèòü ñ öèòèðîâàíèåì
  #708  
Ñòàðûé 10.08.2013, 08:45
Àâàòàð äëÿ angio
angio angio âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 27.04.2010
Ãîðîä: Ïåòðîçàâîäñê
Ñîîáùåíèé: 949
Ñêàçàë(à) ñïàñèáî: 36
Ïîáëàãîäàðèëè 115 ðàç(à) çà 106 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 1
angio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåangio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåangio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåangio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåangio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåangio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåangio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåangio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåangio ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Nastydoc Ïîñìîòðåòü ñîîáùåíèå
Óâàæàåìûå êîëëåãè,! íå íàøëà â îòå÷åñòâåííûõ ðåêîìåíäàöèÿõ èëè ïëîõî ñìîòðåëà - åñëè áîëüíîé íà âàðôàðèíå ñ äîñòèãíóòûì ÌÍÎ ïðåäïîëîæèì 2.5 ïîñòóïàåò ñ ÎÊÑ, ÈÌ
1. íàãðóçî÷íóþ äîçó êëîïèäîãðåëÿ äàâàòü (ïîäîçðåâàþ ÷òî äà)
2. òðîìáîëèçèñ - îòíîñèòåëüíî ïðîòèâîïîêàçàí. ñòàëè áû âû ïðîâîäèòü?
3. ââîäèòü ëè áîëþñ ãåïàðèíà?
4. ïðîâîäèòü ëè èíôóçèþ ãåïàðèíà â äîçàõ, ðåêîìåíäîâàííûõ ïðè îêñ?
5. íèçêîìîëåêóëÿðíûå ãåïàðèíû ñòàëè áû ïðèìåíÿòü?
Ê ñ÷àñòüþ ïàöèåíòîâ ñî STEMI íà àäåêâàòíîé àíòèêîàãóëÿöèè íå ìíîãî. ×òî âïîëíå çàêîíîìåðíî.

"in patients with acute STEMI, when INR is frequently not known: in this situation, regardless of INR values, UFH should be added in moderate doses (e.g. 30–50 U/kg)."

1."Aspirin reduces periprocedural ischaemic complications and should be administered in all patients prior to any PCI procedures. Based on randomised trials and posthoc analyses, pretreatment with clopidogrel is also recommended whenever it can be accomplished. Even if there are no randomised trials on the efficacy and safety of this antiplatelet policy in patients on OAC, analyses from retrospective studies also support this recommendation in this patient group"

2. 3. è 4.
"Current guidelines recommend bridging therapy with unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) to cover the temporary discontinuation of OAC, if the risk of thromboembolism is considered high (8). These recommendations are based on circumstantial evidence and there are no large randomised trials to support the recommendations. Indeed, there are no randomised trials comparing different strategies to manage long-term OAC during PCI. The safety and feasibility of
heparin bridging therapy has been evaluated in patients who receive long-term OAC and require interruption of OAC for elective surgery or an invasive procedure (63–67). Spyropoulos et al. (64)
showed a major bleeding rate of 3.3% with UFH and 5.5% with LMWH in 901 patients with bridging therapy for an elective surgical or invasive procedure. Another recent study (65) reported a 6.7% incidence of major bleeding with LMWH bridging therapy in patients at risk of arterial embolism undergoing elective noncardiac surgery or an invasive procedure, but also lower (2.9%)
rates of major bleeding have been reported. Reports focusing on PCI are limited, but MacDonald et al. (68) reported that 4.2% of 119 patients developed enoxaparin-associated access site complications during LMWH bridging therapy after cardiac catheterisation.
Thus, there is some suggestion that UFH is better than LMWH for bridging to manage OAC for PCI."


5. "Periprocedural anticoagulation has traditionally been performed with UFH or more recently with LMWHs or direct thrombin inhibitors."

P.S.: èñòî÷íèê - [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]


Íó, è êîíå÷íî, ïðåäïî÷òèòåëåí ëó÷åâîé äîñòóï.

Êñòàòè íàøåë â ýòîì äîêóìåíòå ïîëîæåíèå î ïðèìåíåíèè ñòåíòîâ ñ óñêîðåííîé ýíäîòåëèçàöèåé.

"In patients with very high bleeding risk, DES should be avoided (100) and balloon angioplasty (without stenting) is an option if an acceptable result can be achieved. In this case OAC might be combined with aspirin or a thienopyridine ADP-receptor antagonist in the usual dose. If, however, a stent is needed, BMS, especially “less thrombogenic stents” (carbon- or titanium-nitric-oxide-coated stents, stents with biodegradable coating, or antibody-coated stents capturing endothelial progenitor cells may perhaps need a shorter duration of combination antiplatelet therapy. In general, DES should be avoided in patients under OAC at present. However new third generation DES seem to have accelerated re-endothelialisation and might therefore become of interest in the near future. Respective registries (e.g. the Italian MATRIX registry) and trials to test their usefulness are currently performed"
Îòâåòèòü ñ öèòèðîâàíèåì
  #709  
Ñòàðûé 10.08.2013, 10:28
Àâàòàð äëÿ Nastydoc
Nastydoc Nastydoc âíå ôîðóìà ÂÐÀ×
Çàñëóæåííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 18.04.2010
Ãîðîä: Ñàíêò-Ïåòåðáóðã
Ñîîáùåíèé: 607
Ñêàçàë(à) ñïàñèáî: 5
Ïîáëàãîäàðèëè 72 ðàç(à) çà 72 ñîîáùåíèé
Nastydoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNastydoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNastydoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåNastydoc ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Angio, áëàãîäàðþ çà îòâåò!
Îòâåòèòü ñ öèòèðîâàíèåì
  #710  
Ñòàðûé 24.09.2013, 18:35
FisenkoAnna FisenkoAnna âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 24.09.2013
Ãîðîä: Òîìñê
Ñîîáùåíèé: 13
Ñêàçàë(à) ñïàñèáî: 14
FisenkoAnna *
Óâàæàåìûå êîëëåãè! Ó ìåíÿ ïîä íàáëþäåíèåì ïàöèåíòêà Ë. 72-õ ëåò. ÅÅ äèàãíîç: ÈÁÑ: ïîñòîÿííàÿ ôîðìà ôèáðèëëÿöèè ïðåäñåðäèé, íîðìîôîðìà, ÕÑÍ II À, ÔÊ III, ôîí: ãèïåðòîíè÷åñêàÿ áîëåçíü III ñòàäèÿ, ðèñê4.…ÎÍÌÊ (05.2013ã.)
ß ïðèìåíèëà ê íåé ñëåäóþùóþ ëåêàðñòâåííóþ òåðàïèþ:äèãîêñèí ïî 0,5 òàáëåòêè óòðîì, ãèïîòèàçèä 25 ìã-1 òàáë. óòðîì, êîíêîð 20 ìã. óòðîì, ðåíèïðèë 20ìã., êàðäèîìàãíèë 75 ìã. â îáåä, ðåíèïðèë 20 ìã. âå÷åð, êàïîòåí è ôèçèîòåíç ïðè ïîâûøåíèè äàâëåíèÿ â òå÷åíèè äíÿ âûøå, ÷åì 140/90
Ïàöèåíòêà â òå÷åíèå ñóòîê èçìåðÿåò ÀÄ, öèôðû íà òàêîé òåðàïèè äîñòèãàþò è 180 è200/100-110 Îòìå÷àþò ðîäñòâåííèêè, ÷òî ïðè ðàçãàäûâàíèè ïàççëîâ, ëèáî êàêîé-ëèáî äðóãîé óìñòâåííîé (ïîñèëüíîé ïîñëå ïåðåíåñåííîãî èíñóëüòà)ðàáîòîé, óðîâåíü àðòåðèàëüíîãî äàâëåíèÿ 120-130/80-90 Ïîäñêàæèòå, êàêîâà ìîæåò áûòü êîððåêöèÿ ìîåé òåðàïèè, ÷òîáû â ýòîì ñëó÷àå äîñòèãíóòü öåëåâîãî óðîâíÿ ÀÄ? Ïîæàëóéñòà!
Îòâåòèòü ñ öèòèðîâàíèåì
  #711  
Ñòàðûé 24.09.2013, 19:13
Àâàòàð äëÿ Korzun
Korzun Korzun âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 15.03.2005
Ãîðîä: Ãåðìàíèÿ
Ñîîáùåíèé: 24,467
Ñêàçàë(à) ñïàñèáî: 1
Ïîáëàãîäàðèëè 10,461 ðàç(à) çà 9,629 ñîîáùåíèé
Korzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò FisenkoAnna Ïîñìîòðåòü ñîîáùåíèå
ïîñòîÿííàÿ ôîðìà ôèáðèëëÿöèè ïðåäñåðäèé, ÎÍÌÊ (05.2013ã.)
êàðäèîìàãíèë 75 ìã.
â îáåä, ïîñèëüíîé ïîñëå ïåðåíåñåííîãî èíñóëüòà
À ãäå ÂÀÐÔÀÐÈÍ ???
__________________
Àëåêñàíäð Èâàíîâè÷
ñ ïîæåëàíèÿìè êðåïêîãî çäîðîâüÿ
Îòâåòèòü ñ öèòèðîâàíèåì
  #712  
Ñòàðûé 24.09.2013, 19:22
Igor73 Igor73 âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 17.03.2005
Ãîðîä: Ìîñêâà
Ñîîáùåíèé: 1,195
Ïîáëàãîäàðèëè 69 ðàç(à) çà 53 ñîîáùåíèé
Igor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIgor73 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò FisenkoAnna Ïîñìîòðåòü ñîîáùåíèå
Óâàæàåìûå êîëëåãè! Ó ìåíÿ ïîä íàáëþäåíèåì ïàöèåíòêà Ë. 72-õ ëåò. ÅÅ äèàãíîç: ÈÁÑ: ïîñòîÿííàÿ ôîðìà ôèáðèëëÿöèè ïðåäñåðäèé, íîðìîôîðìà, ÕÑÍ II À, ÔÊ III, ôîí: ãèïåðòîíè÷åñêàÿ áîëåçíü III ñòàäèÿ, ðèñê4.…ÎÍÌÊ (05.2013ã.)
ß ïðèìåíèëà ê íåé ñëåäóþùóþ ëåêàðñòâåííóþ òåðàïèþ:äèãîêñèí ïî 0,5 òàáëåòêè óòðîì, ãèïîòèàçèä 25 ìã-1 òàáë. óòðîì, êîíêîð 20 ìã. óòðîì, ðåíèïðèë 20ìã., êàðäèîìàãíèë 75 ìã. â îáåä, ðåíèïðèë 20 ìã. âå÷åð, êàïîòåí è ôèçèîòåíç ïðè ïîâûøåíèè äàâëåíèÿ â òå÷åíèè äíÿ âûøå, ÷åì 140/90
Ïàöèåíòêà â òå÷åíèå ñóòîê èçìåðÿåò ÀÄ, öèôðû íà òàêîé òåðàïèè äîñòèãàþò è 180 è200/100-110 Îòìå÷àþò ðîäñòâåííèêè, ÷òî ïðè ðàçãàäûâàíèè ïàççëîâ, ëèáî êàêîé-ëèáî äðóãîé óìñòâåííîé (ïîñèëüíîé ïîñëå ïåðåíåñåííîãî èíñóëüòà)ðàáîòîé, óðîâåíü àðòåðèàëüíîãî äàâëåíèÿ 120-130/80-90 Ïîäñêàæèòå, êàêîâà ìîæåò áûòü êîððåêöèÿ ìîåé òåðàïèè, ÷òîáû â ýòîì ñëó÷àå äîñòèãíóòü öåëåâîãî óðîâíÿ ÀÄ? Ïîæàëóéñòà!
Ñíèæåíèå ÀÄ äî íîðìû ìîæåò ãîâîðèòü î ñëåäóþùåì:
1) íåïðàâèëüíî èçìåðÿåòñÿ ÀÄ (ñì. ïî êðåïëåííûå òåìû â ðàçäåëå êàðäèîëîãèÿ)
2) âûñîêàÿ ýìîöèîíàëüíàÿ ëàáèëüíîñòü, ýìîöèîíàëüíûé ñòðåññ
Åñëè ýòè ôàêòû íå ó÷åñòü è îðèåíòèðîâàòüñÿ íà 180-200 Hg, òî Âû áóäåòå ïåðåëå÷èâàòü ïàöèåíòêó.
Ïðåäëàãàþ ïðîâåñòè ÑÌÀÄ è îðèåíòèðîâàòüñÿ íà ñðåäíèå öèôðû çà ñóòêè.
Íîðìà - îñòàâèòü âñå êàê åñòü
Âûñîêèå öèôðû - êîððåêöèÿ
Âûñîêàÿ ëàáèëüíîñòü ÀÄ - ïîãîâîðèòü ñ ïàöèåíòêîé, ðîäñòâåííèêàìè è ïîäóìàòü î àíòèäåïðåññàíòàõ/êëîíàçåïàìå.

Êîììåíòàðèè ê ñîîáùåíèþ:
Yariko îäîáðèë(à):
Îòâåòèòü ñ öèòèðîâàíèåì
  #713  
Ñòàðûé 25.09.2013, 17:20
FisenkoAnna FisenkoAnna âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 24.09.2013
Ãîðîä: Òîìñê
Ñîîáùåíèé: 13
Ñêàçàë(à) ñïàñèáî: 14
FisenkoAnna *
Ñïàñèáî!

Ñïàñèáî çà îòâåòû, ó÷òó!
Îòâåòèòü ñ öèòèðîâàíèåì
  #714  
Ñòàðûé 25.09.2013, 18:08
Àâàòàð äëÿ Korzun
Korzun Korzun âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 15.03.2005
Ãîðîä: Ãåðìàíèÿ
Ñîîáùåíèé: 24,467
Ñêàçàë(à) ñïàñèáî: 1
Ïîáëàãîäàðèëè 10,461 ðàç(à) çà 9,629 ñîîáùåíèé
Korzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò FisenkoAnna Ïîñìîòðåòü ñîîáùåíèå
ÈÁÑ: ïîñòîÿííàÿ ôîðìà ôèáðèëëÿöèè ïðåäñåðäèé, íîðìîôîðìà, ÕÑÍ II À, ÔÊ III, ôîí: ãèïåðòîíè÷åñêàÿ áîëåçíü III ñòàäèÿ, ðèñê4.…ÎÍÌÊ (05.2013ã.)
êàðäèîìàãíèë 75 ìã.
Ïîäðîáíåå î Âàðôàðèíå â äàííîì ñëó÷àå.

Øêàëà ðàñ÷åòà ðèñêà èíñóëüòà ïðè ÔÏ:
[Èçîáðàæåíèÿ äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì]

ß íàñ÷èòàë 8 áàëëîâ (èç 9 âîçìîæíûõ!, åñëè òîëüêî äèàáåòà äåéñòâèòåëüíî íåò)!
Ïàöèåíòêå íóæíà íå ñìåøíàÿ äîçà ñîìíèòåëüíîãî ãåíåðèêà àñïèðèíà, à ÂÀÐÔÀÐÈÍ ñ ïîäáîðîì ïî ÌÍÎ 2-3! È Âàðôàðèí íóæåí óæå â÷åðà...
__________________
Àëåêñàíäð Èâàíîâè÷
ñ ïîæåëàíèÿìè êðåïêîãî çäîðîâüÿ
Îòâåòèòü ñ öèòèðîâàíèåì
  #715  
Ñòàðûé 25.09.2013, 18:27
FisenkoAnna FisenkoAnna âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
 
Ðåãèñòðàöèÿ: 24.09.2013
Ãîðîä: Òîìñê
Ñîîáùåíèé: 13
Ñêàçàë(à) ñïàñèáî: 14
FisenkoAnna *
Ïîñîâåòóéòå, ñ êàêîé äîçèðîâêè âàðôàðèíà ìíå íóæíî íà÷àòü, òÿíó ñ åãî íàçíà÷åíèåì ëèøü ïîòîìó, ÷òî ïàöèåíòêó íàáëþäàþ íà äîìó-ïîêà íåò âîçìîæíîñòè èçìåðèòü ÌÍÎ
Îòâåòèòü ñ öèòèðîâàíèåì
  #716  
Ñòàðûé 25.09.2013, 18:39
Àâàòàð äëÿ Korzun
Korzun Korzun âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 15.03.2005
Ãîðîä: Ãåðìàíèÿ
Ñîîáùåíèé: 24,467
Ñêàçàë(à) ñïàñèáî: 1
Ïîáëàãîäàðèëè 10,461 ðàç(à) çà 9,629 ñîîáùåíèé
Korzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Íà÷àëüíàÿ äîçà äëÿ ïàöèåíòîâ, êîòîðûå ðàíåå íå ïðèìåíÿëè âàðôàðèí, ñîñòàâëÿåò 5 ìã/ (2 òàáëåòêè) â òå÷åíèå ïåðâûõ 4-õ äíåé. Íà 5-é äåíü ëå÷åíèÿ îïðåäåëÿåòñÿ MHO è, â ñîîòâåòñòâèè ñ ýòèì ïîêàçàòåëåì, íàçíà÷àåòñÿ ïîääåðæèâàþùàÿ äîçà ïðåïàðàòà. Îáû÷íî ïîääåðæèâàþùàÿ äîçà ïðåïàðàòà ñîñòàâëÿåò 2.5-7.5 ìã/ (1-3 òàáëåòêè).
Áåç ÌÍÎ íèêàê.
Èíôîðìèðóþ, ÷òî ñóùåñòâóþò ïðèáîðû äëÿ äîìàøíåãî èçìåðåíèÿ ÌÍÎ (êîàãó÷åê, ïî òèïó äîìàøíåãî èçìåðåíèÿ ñàõàðà: êàïëÿ íà òåñò-ïîëîñêó). Îíè äîðîãîñòîÿùèå, íî åñëè ïàöèåíòêå èëè ðîäñòâåííèêàì ïî êàðìàíó, òî ýòî âàðèàíò àäåêâàòíîãî êîíòðîëÿ ÌÍÎ íà äîìó.
Êðîìå òîãî, ñóùåñòâóþò ðàçíûå ïëàòíûå ëàáîðàòîðèè (ïðî Òîìñê íå çíàþ) ñ âîçìîæíîñòüþ çàáîðà êðîâè íà äîìó.

×åì ÷àùå è íàâÿç÷èâåå êîíòðîëèðóåòñÿ ÌÍÎ, òåì ìåíüøå øàíñîâ íà îñëîæíåíèÿ è òåì ëó÷øå âûæèâàåìîñòü.

Êîììåíòàðèè ê ñîîáùåíèþ:
Dr.Vad îäîáðèë(à):
__________________
Àëåêñàíäð Èâàíîâè÷
ñ ïîæåëàíèÿìè êðåïêîãî çäîðîâüÿ
Îòâåòèòü ñ öèòèðîâàíèåì
  #717  
Ñòàðûé 25.09.2013, 22:05
disdas disdas âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 15.06.2009
Ãîðîä: Óêðàèíà, Ëóãàíñê
Ñîîáùåíèé: 345
Ïîáëàãîäàðèëè 127 ðàç(à) çà 123 ñîîáùåíèé
disdas ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådisdas ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådisdas ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådisdas ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìådisdas ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Íåò âåðîøïèðîíà , òèàçèä çàìåíèòü íà ïîñòîÿííûé òîðàñåìèä, äîáàâèòü àíòàãîíèñòû êàëüöèÿ..... åùå ìíîãî ÷åãî ìîæíî äëÿ íîðìàëèçàöèè ÀÄ. À âîò êàïòîïðèë ýïèçîäè÷åñêè è òîëüêî êàê ðåàêöèÿ íà öèôðû òîíîìåòðà -ýòî òî÷íî ðàñøàòûâàåò ãèïåðòîíèþ âñëåäñòâèè íåïðîäîëæèòåëüíîãî ïåðèîäà äåéñòâèÿ.
Áèñîïðîëîë ìîæíî ðàçäåëèòü íà 2 ïðèåìà, ìåíüøå áóäåò ïèêîâàÿ ãèïîòåíçèÿ óòðîì(+ ýíàëàïðèë).
Âàðôàðèí íåîáõîäèì îäíîçíà÷íî.
Îòâåòèòü ñ öèòèðîâàíèåì
  #718  
Ñòàðûé 26.09.2013, 04:43
BMB BMB âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 12.10.2010
Ãîðîä: Êðàñíîÿðñê
Ñîîáùåíèé: 276
Ñêàçàë(à) ñïàñèáî: 113
Ïîáëàãîäàðèëè 15 ðàç(à) çà 15 ñîîáùåíèé
BMB ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBMB ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBMB ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBMB ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Óâàæàåìûå êîëëåãè, ÿ âñ¸ î òîì æå
Management of Patients With Atrial Fibrillation ACC/AHA îò àïðåëÿ 2013 ã.: in patients with AF associated with thyrotoxicosis, oral anticoagulation (iNr 2.0 to 3.0) is recommended to prevent thromboembolism, as recommended for AF patients with other risk factors for stroke. (Level of Evidence: C)
4. once a euthyroid state is restored, recommendations for antithrombotic prophylaxis are the same as for patients without hyperthyroidism. (Level of Evidence: C) - ÷òî ÿ ïîíÿë ïðèáëèçèòåëüíî òàê "ïåðîðàëüíàÿ àíòèêîàãóëÿöèÿ ïàöèåíòàì ñ ô. ï. íà ôîíå òèðåîòîêñèêîçà ïîêàçàíà òàê æå, êàê ïàöèåíòàì ñ äðóãèìè ôàêòîðàìè ðèñêà ïðè ô. ï. Ïîñëå äîñòèæåíèÿ ýóòèðåîçà âîïðîñ îá àíòèêîàãóëÿöèè - òàê æå êàê ó îñòàëüíûõ ïàöèåíòîâ áåç òèðåîòîêñèêîçà"
Guidelines for the management of atrial fibrillation ESC 2010 ã.:
In patients with active thyroid disease, antithrombotic therapy is recommended based on the presence of other stroke risk factors. (I C) - "ó ïàöèåíòîâ ñ àêòèâíûì çàáîëåâàíèåì ùèòîâèäíîé æåëåçû àíòèêîàãóëÿíòíóþ òåðàïèþ ðåêîìåíäóåì ïðè íàëè÷èè äðóãèõ ôàêòîðîâ ðèñêà"
ß ïðàâèëüíî ïîíèìàþ, ÷òî ïî ýòîìó âîïðîñó êîëëåêòèâíîå ìíåíèå àìåðèêàíñêèõ ýêñïåðòîâ ïðîòèâîïîëîæíî êîëëåêòèâíîìó ìíåíèþ åâðîïåéñêèõ?
Îòâåòèòü ñ öèòèðîâàíèåì
  #719  
Ñòàðûé 26.09.2013, 07:12
Àâàòàð äëÿ Korzun
Korzun Korzun âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 15.03.2005
Ãîðîä: Ãåðìàíèÿ
Ñîîáùåíèé: 24,467
Ñêàçàë(à) ñïàñèáî: 1
Ïîáëàãîäàðèëè 10,461 ðàç(à) çà 9,629 ñîîáùåíèé
Korzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåKorzun ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò BMB Ïîñìîòðåòü ñîîáùåíèå
ß ïðàâèëüíî ïîíèìàþ, ÷òî ïî ýòîìó âîïðîñó êîëëåêòèâíîå ìíåíèå àìåðèêàíñêèõ ýêñïåðòîâ ïðîòèâîïîëîæíî êîëëåêòèâíîìó ìíåíèþ åâðîïåéñêèõ?
Íå óâèäåë ïðîòèâîðå÷èé è ïðîòèâîïîëîæíîñòåé.
__________________
Àëåêñàíäð Èâàíîâè÷
ñ ïîæåëàíèÿìè êðåïêîãî çäîðîâüÿ
Îòâåòèòü ñ öèòèðîâàíèåì
  #720  
Ñòàðûé 26.09.2013, 07:56
BMB BMB âíå ôîðóìà ÂÐÀ×
Ïîñòîÿííûé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 12.10.2010
Ãîðîä: Êðàñíîÿðñê
Ñîîáùåíèé: 276
Ñêàçàë(à) ñïàñèáî: 113
Ïîáëàãîäàðèëè 15 ðàç(à) çà 15 ñîîáùåíèé
BMB ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBMB ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBMB ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåBMB ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Öèòàòà:
Ñîîáùåíèå îò Korzun Ïîñìîòðåòü ñîîáùåíèå
Íå óâèäåë ïðîòèâîðå÷èé è ïðîòèâîïîëîæíîñòåé.
íàñêîëüêî ÿ ïîíÿë, àìåðèêàíöû ñ÷èòàþò òèðåòîêñèêîç äîïîëíèòåëüíûì ïîêàçàíèåì ê ïåðîðàëüíûì àíòèêîàãóëÿíòàì ïðè ô. ï. (ðåêîìåíäóåòñÿ íàçíà÷àòü òàê æå, êàê è ïðè íàëè÷èè äðóãèõ ôàêòîðîâ ðèñêà) Åâðîïåéöû â òàêîé æå ñèòóàöèè ïðåäëàãàþò ðåøàòü âîïðîñ îá àíòèêîàãóëÿíòàõ íåçàâèñèìî îò óðîâíÿ àêòèâíîñòè ùèòîâèäíîé æåëåçû.
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 10:29.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.